<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIHEXYPHENIDYL HYDROCHLORIDE- trihexyphenidyl hydrochloride solution </strong><br>Mikart, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_117feed2-ba77-4729-aca4-f70a12306dfb"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Trihexyphenidyl Hydrochloride Oral Solution USP is a synthetic antispasmodic drug. It is designated chemically as α-Cyclohexyl-α-phenyl-1-piperidinepropanol hydrochloride and its structural formula is as follows:</p>
<div class="Figure">
<a name="id86007860"></a><img alt="trihexyphenidyl hydrochloride chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6f08000-e973-4bab-810c-b69f6c8ee4f3&amp;name=8b5d1f1c-5c95-428e-90fd-842b78338892-01.jpg">
</div>
<p>C<span class="Sub">20</span>H<span class="Sub">31</span>NO•HCl</p>
<p>M.W. 337.93</p>
<p>Trihexyphenidyl hydrochloride occurs as a white or creamy-white, almost odorless, crystalline powder. It is very slightly soluble in ether and benzene, slightly soluble in water and soluble in methanol.</p>
<p>Each 5 mL (teaspoonful) for oral administration contains 2 mg trihexyphenidyl hydrochloride and alcohol 5% in a clear, colorless, lime-mint flavored preparation. In addition, it contains the following inactive ingredients: citric acid, flavoring, methylparaben, propylparaben, purified water and sorbitol solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_1312c9e9-ff3d-486c-9732-844d17cea4e9"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Trihexyphenidyl exerts a direct inhibitory effect upon the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly upon the muscle tissue itself and indirectly through an inhibitory effect upon the parasympathetic nervous system. Its therapeutic properties are similar to those of atropine although undesirable side effects are ordinarily less frequent and severe than with the latter.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_004b15a2-b8e3-4394-a3ee-d7e77f7f89ae"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> with levodopa. Additionally, it is indicated for the control of <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_b95b3ced-4f04-44e2-9c23-91f280e6097b"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Trihexyphenidyl is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trihexyphenidyl or to any of the other ingredients. Trihexyphenidyl is also contraindicated in patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span> after long-term use due to narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> has been reported.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_7c639666-51ca-4826-97ef-01da4c5f0647"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Patients to be treated with trihexyphenidyl should have a gonioscope evaluation prior to initiation of therapy and close monitoring of intraocular pressures. The use of anticholinergic drugs may precipitate angle closure with an increase in intraocular pressure. If <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> occurs during therapy, the possibility of narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> should be considered. <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span> has been reported due to aggravation of narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. (See <span class="Bold"><a href="#ID_b95b3ced-4f04-44e2-9c23-91f280e6097b">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#ID_f496c938-788d-41d3-a81b-1941a1ead5cb">ADVERSE REACTIONS</a></span>).</p>
<p>Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">Anhidrosis</span> may occur more readily when some disturbance of <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> already exists. If there is evidence of <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span>, the possibility of <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> should be considered. Dosage should be decreased so that the ability to maintain body heat equilibrium via perspiration is not impaired. Severe <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span> and fatal <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> have occurred with the use of anticholinergics under the conditions described above.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_26074808-e433-4b32-907b-a48a2db0fc01"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system (CNS) pathology.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_31afde45-a949-42d8-96f3-729471294fc8"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_ae2f76bd-a84e-4649-9588-3a37f8b4e28f"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Patients with cardiac, liver, or kidney disorders, or with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, should be closely monitored.</p>
<p>Since trihexyphenidyl has atropine-like properties, patients on long-term treatment should be carefully monitored for untoward reactions.</p>
<p>Since trihexyphenidyl has parasympatholytic activity, it should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, obstructive disease of the gastrointestinal or genitourinary tracts, and in elderly males with possible <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>. Incipient <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may be precipitated by parasympatholytic drugs such as trihexyphenidyl.</p>
<p><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> may appear in some patients on long-term therapy with antipsychotic drugs or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, and in some instances may aggravate them.</p>
<p>However, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> often coexist in patients receiving chronic neuroleptic treatment, and anticholinergic therapy with trihexyphenidyl may relieve some of these <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> symptoms. Trihexyphenidyl is not recommended for use in patients with <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> unless they have concomitant Parkinson's disease.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span> or with a history of idiosyncrasy to other drugs may exhibit reactions of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, disturbed behavior, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Such patients should be allowed to develop a tolerance through the initial administration of a small dose and gradual increase in dose until an effective level is reached. If a severe reaction should occur, administration of the drug should be discontinued for a few days and then resumed at a lower dosage. Psychiatric disturbances can result from indiscriminate use (leading to overdosage) to sustain continued <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>. (See <span class="Bold"><a href="#ID_06f76cff-bcf3-481f-96b7-65929c92da50">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>).</p>
<p>Abrupt withdrawal of treatment for <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> may result in acute exacerbation of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> symptoms; therefore, abrupt withdrawal should be avoided (See <span class="Bold"><a href="#ID_d4343349-06ee-4418-9e47-d99dc8ee2f8b">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_c36c5f5b-c016-4e2d-be88-dcf1391a6804"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Trihexyphenidyl may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that trihexyphenidyl therapy does not adversely affect their ability to engage in such activities.</p>
<p>Because of increased sedative effects, patients should be cautioned to avoid the use of alcohol or other CNS depressants while taking trihexyphenidyl.</p>
<p>Since this medication may increase the susceptibility to <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> (gastrointestinal (GI) problems, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, heat intolerance), use with caution during hot weather. (See <span class="Bold"><a href="#ID_7c639666-51ca-4826-97ef-01da4c5f0647">WARNINGS</a></span>).</p>
<p>Patients should be advised to report the occurrence of GI problems, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or heat intolerance promptly since <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> may occur.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">GI upset</span> occurs, trihexyphenidyl may be taken with food.</p>
<p>Patients should have close monitoring of intraocular pressure. (See <span class="Bold"><a href="#ID_7c639666-51ca-4826-97ef-01da4c5f0647">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_623ad94d-d765-4925-a72f-505daf7611f0"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists.</p>
<p>Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects.</p>
<p>Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications.</p>
<p><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration of anticholinergic agents, such as trihexyphenidyl, as a prevention of drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> during neuroleptic therapy is not recommended. There may be an increased risk for the development of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> during concomitant administration of anticholinergics and neuroleptics (See <span class="Bold"><a href="#ID_ae2f76bd-a84e-4649-9588-3a37f8b4e28f">PRECAUTIONS, General</a></span>).</p>
<p>The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See <span class="Bold"><a href="#ID_d4343349-06ee-4418-9e47-d99dc8ee2f8b">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_d799d618-0062-4ce0-bcc6-82a9605d7dc4"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies or adequate genotoxicity or fertility studies have been conducted for trihexyphenidyl.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_c5c10344-68d2-4cd4-8a43-d0584073a9af"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_3d296ca8-26f6-4724-bb69-299a69ef0817"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_302fa2f3-e37b-4247-92e1-d21b187952f0"></a><a name="section-6.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies to evaluate teratogenic and embryotoxic potential have not been conducted with trihexyphenidyl. It is also not known whether trihexyphenidyl can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Trihexyphenidyl should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_09f32e4d-7bf0-4d06-b47d-73e8ec0951d8"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when trihexyphenidyl is administered to a nursing woman.</p>
<p>As with other anticholinergics, trihexyphenidyl may cause suppression of lactation. Therefore, trihexyphenidyl should only be used if the expected benefit to the mother outweighs the potential risk to the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_eee11fe2-7f6a-42b6-82a1-763c3a400d9f"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. (See also <span class="Bold"><a href="#ID_f496c938-788d-41d3-a81b-1941a1ead5cb">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_3ddae1de-1480-4b28-b414-3495d81d11f8"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Sensitivity to the actions of parasympatholytic drugs may increase with age, particularly over the age of 60; therefore, elderly patients generally should be started on low doses of trihexyphenidyl and observed closely.</p>
<p>Trihexyphenidyl has been shown to cause some cognitive dysfunctions in the elderly, including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>. (See <span class="Bold"><a href="#ID_f496c938-788d-41d3-a81b-1941a1ead5cb">ADVERSE REACTIONS</a></span> and <span class="Bold"><a href="#ID_d4343349-06ee-4418-9e47-d99dc8ee2f8b">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_f496c938-788d-41d3-a81b-1941a1ead5cb"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Minor side effects, such as dryness of the mouth, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, will be experienced by 30 to 50 percent of all patients. These sensations, however, are much less troublesome with trihexyphenidyl than with belladonna alkaloids and are usually less disturbing than unalleviated <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>. Such reactions tend to become less pronounced, and even to disappear, as treatment continues. Even before these reactions have remitted spontaneously, they may often be controlled by careful adjustment of dosage form, amount of drug, or interval between doses.</p>
<p>Isolated instances of suppurative <span class="product-label-link" type="condition" conceptid="4032796" conceptname="Parotitis">parotitis</span> secondary to excessive dryness of the mouth, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, dilatation of the colon, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, and certain psychiatric manifestations such as <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, all of which may occur with any of the atropine-like drugs, have been reported rarely with trihexyphenidyl.</p>
<p>Potential side effects associated with the use of any atropine-like drugs, including trihexyphenidyl, include cognitive dysfunctions, including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> or retention, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, dilation of the pupil, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, choreiform movements, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Exacerbation of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> with abrupt treatment withdrawal has been reported. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> with abrupt treatment withdrawal has been reported (See <span class="Bold"><a href="#ID_26074808-e433-4b32-907b-a48a2db0fc01">WARNINGS, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></span>).</p>
<p>The occurrence of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> in patients receiving trihexyphenidyl has been reported (<span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> has been reported in some cases). Paradoxical <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, and <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> have been reported.</p>
<p>In addition to adverse events seen in adults, the following adverse events have been reported in the literature in pediatric patients: <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, and sleep alterations.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_06f76cff-bcf3-481f-96b7-65929c92da50"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Although trihexyphenidyl is not classified as a controlled substance, the possibility of abuse should be borne in mind due to its stimulant and euphoriant properties.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_730d9e00-c86f-4b19-ac8c-69e811a49061"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The mean oral LD<span class="Sub">50</span> of trihexyphenidyl has been reported to be 365 mg/kg (range, 325 to 410 mg/kg) in mice and 1660 mg/kg (1420 to 1940 mg/kg) in rats. At a dose of 40 mg/kg, dogs have exhibited <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, equilibrium disturbances, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.</p>
<p>In humans, doses up to 300 mg (5 mg/kg) have been ingested without fatalities or sequelae. However, rare cases of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with trihexyphenidyl overdosages taken in conjunction with other CNS-depressant agents have been reported or in patients with a compromised respiratory condition. Trihexyphenidyl blood concentrations associated with the fatalities ranged from 0.03 to 0.80 mg/l.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_897645c1-16ad-4f0a-ba5a-555ac71f974c"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Overdosage with trihexyphenidyl produces typical central symptoms of atropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> (the central anticholinergic syndrome). Correct diagnosis depends upon recognition of the peripheral signs of parasympathetic blockade, including dilated and sluggish pupils; warm, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>; decreased secretions of the mouth, pharynx, nose, and bronchi; foul-smelling breath; elevated temperature; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>; decreased bowel sounds; and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Neuropsychiatric signs such as <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusions</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, incoherence, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, lip smacking and tasting movements, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">loss of memory</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, combativeness, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be present. The condition can progress to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, cardiac and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c5770ec1-518f-4cfa-b6a4-fdfbe7c14882"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> involves symptomatic and supportive therapy. Gastric lavage or other methods to limit absorption should be instituted. A small dose of diazepam or a short-acting barbiturate may be administered if CNS excitation is observed. Phenothiazines are contraindicated because the toxicity may be intensified due to their antimuscarinic action, causing <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Respiratory support, artificial respiration or vasopressor agents may be necessary. <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> must be reversed, fluid volume replaced and acid-balance maintained. Urinary catheterization may be necessary. It is not known if trihexyphenidyl is dialyzable</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_d4343349-06ee-4418-9e47-d99dc8ee2f8b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be individualized. The initial dose should be low and then increased gradually, especially in patients over 60 years of age. Whether trihexyphenidyl may best be given before or after meals should be determined by the way the patient reacts. Postencephalitic patients, who are usually more prone to excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, may prefer to take it after meals and may, in addition, require small amounts of atropine which, under such circumstances, is sometimes an effective adjuvant. If trihexyphenidyl tends to dry the mouth excessively, it may be better to take it before meals, unless it causes <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. If taken after meals, the <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> sometimes induced can be allayed by mint candies, chewing gum or water.</p>
<p>Abrupt withdrawal of treatment for <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> may result in acute exacerbation of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> symptoms; therefore, abrupt withdrawal should be avoided.</p>
<p>Abrupt withdrawal of treatment may result in <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS) (See <span class="Bold"><a href="#ID_7c639666-51ca-4826-97ef-01da4c5f0647">WARNINGS</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1af13e6f-9895-4197-aa7c-47527b0aaf17"></a><a name="section-10.1"></a><p></p>
<h2>Idiopathic <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></h2>
<p class="First">As initial therapy for <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, 1 mg of trihexyphenidyl hydrochloride may be administered the first day. The dose may then be increased by 2 mg increments at intervals of three to five days, until a total of 6 to 10 mg is given daily. The total daily dose will depend upon what is found to be the optimal level. Many patients derive maximum benefit from this daily total of 6 to 10 mg, but some patients, chiefly those in the postencephalitic group, may require a total daily dose of 12 to 15 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_92f4bdea-70e5-4728-b073-396813cfa397"></a><a name="section-10.2"></a><p></p>
<h2>Drug-Induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></h2>
<p class="First">The size and frequency of the trihexyphenidyl dose needed to control extrapyramidal reactions to commonly employed tranquilizers, notably the phenothiazines, thioxanthenes, and butyrophenones, must be determined empirically. The total daily dosage usually ranges between 5 and 15 mg although, in some cases, these reactions have been satisfactorily controlled with as little as 1 mg daily. It may be advisable to commence therapy with a single 1 mg dose. If the extrapyramidal manifestations are not controlled in a few hours, the subsequent doses may be progressively increased until satisfactory control is achieved. Satisfactory control may sometimes be more rapidly achieved by temporarily reducing the dosage of the tranquilizer when instituting trihexyphenidyl therapy and then adjusting the dosage of both drugs until the desired ataractic effect is retained without onset of extrapyramidal reactions.</p>
<p>It is sometimes possible to maintain the patient on a reduced trihexyphenidyl dosage after the reactions have remained under control for several days. Instances have been reported in which these reactions have remained in remission for long periods after trihexyphenidyl therapy was discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1ad125f0-87ab-45b3-8375-d87771675efe"></a><a name="section-10.3"></a><p></p>
<h2>Concomitant Use with Levodopa</h2>
<p class="First">When trihexyphenidyl is used concomitantly with levodopa, the usual dose of each may need to be reduced. Careful adjustment is necessary, depending on side effects and degree of symptom control. A trihexyphenidyl dosage of 3 to 6 mg daily, in divided doses, is usually adequate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_110d6986-6893-4c63-9200-52ff34c9e84b"></a><a name="section-10.4"></a><p></p>
<h2>Concomitant Use with Other Parasympathetic Inhibitors</h2>
<p class="First">Trihexyphenidyl may be substituted, in whole or in part, for other parasympathetic inhibitors. The usual technique is partial substitution initially, with progressive reduction in the other medication as the dose of trihexyphenidyl is increased.</p>
<p>The total daily intake of trihexyphenidyl hydrochloride oral solution USP is tolerated best if divided into 3 doses and taken at mealtimes. High doses (&gt;10 mg daily) may be divided into 4 parts, with 3 doses administered at mealtimes and the fourth at bedtime</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_53c483b9-0e55-424f-8d34-36daee257213"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Trihexyphenidyl Hydrochloride Oral Solution, containing trihexyphenidyl 2 mg per 5 mL, is a clear, colorless, lime-peppermint flavored liquid supplied in 473 mL (16 fl. oz.) bottles, NDC 46672-635-16.</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. </p>
<p><span class="Bold">DO NOT FREEZE. </span></p>
<p>Rx Only</p>
<p>Manufactured By:</p>
<p><span class="Bold">Mikart</span><span class="Bold">, Inc. </span></p>
<p>Atlanta, GA 30318</p>
<p>Code 734Z00</p>
<p>Rev. 12/12</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0b82e834-4107-43ef-be21-ce3777415aa5"></a><a name="section-12"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id2626707"></a><img alt="container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6f08000-e973-4bab-810c-b69f6c8ee4f3&amp;name=8b5d1f1c-5c95-428e-90fd-842b78338892-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIHEXYPHENIDYL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">trihexyphenidyl hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:46672-635</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIHEXYPHENIDYL HYDROCHLORIDE</strong> (TRIHEXYPHENIDYL) </td>
<td class="formItem">TRIHEXYPHENIDYL HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">LIME (LIME-PEPPERMINT) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:46672-635-16</td>
<td class="formItem">473 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040251</td>
<td class="formItem">10/04/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mikart, Inc.
							(030034847)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8b5d1f1c-5c95-428e-90fd-842b78338892</div>
<div>Set id: d6f08000-e973-4bab-810c-b69f6c8ee4f3</div>
<div>Version: 1</div>
<div>Effective Time: 20130412</div>
</div>
</div> <div class="DistributorName">Mikart, Inc.</div></p>
</body></html>
